Hemispherx Biopharma Press Release
Philadelphia, PA, Wednesday, November 10, 2010: Hemispherx Biopharma, Inc. (NYSE Amex: HEB) announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen® and Alferon® development programs.
These awards were approved by the Internal Revenue Service (IRS), in conjunction with the Department of Heath and Human Services (DHHS), under the Qualifying Therapeutic Discovery Project Program, established under the Patient Protection and Affordable Care Act of 2010 for projects that showed significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness.
The amounts granted for these two Hemispherx projects were for the maximum per-project amount set by the IRS based on the limited amount of funds allocated for the program.
Read more>>
Doctor Speedy and ME in search of medical honesty
No comments:
Post a Comment